Advaxis Engages The Numoda Corporation To Oversee Phase II Clinical Trials Of ADXS11-001

Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Clinical Trials / Drug Trials
Article Date: 25 Jun 2009 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia).

Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved.

"The Numoda Corporation offers experience and resources that will enable Advaxis to execute multiple high quality clinical trials with precision, efficiency, high quality data and a rapid final study report," commented Advaxis EVP of Science and Operations Dr. John Rothman.

Advaxis anticipates that the Numoda Corporation's involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company's most recent 10-Q filing. For more information on public filing documents, please visit the US Security and Exchange Commission's website at: http://www.sec.gov.

Source
Numoda Corporation
Advaxis, Incorporated